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Abstract
Background:  Acute inflammatory polyradiculoneuropathy secondary to chemotherapy for
leukemia has been described in the pediatric literature. However, the reports are rare and have
been mainly from intrathecal methotrexate in pediatric acute lymphoblastic leukemia patients who
developed demyelinating polyradiculoneuropathy.
Case presentation: A case report is presented of an unfortunate 53 year old Hispanic woman
with acute myelogenous leukemia who developed profound weakness with cranial nerve palsies
following both intravenous and intrathecal chemotherapy.
Conclusion: This is an interesting and unusual case of predominantly axonal ascending sensory
motor polyradiculoneuropathy with cranial nerve involvement in an adult patient with acute
myelogenous leukemia following intravenous Cytosine arabinoside and intrathecal methotrexate.
Background
Polyradiculoneuropathies and ascending motor paraple-
gia have been described in pediatric leukemia patients
undergoing chemotherapy. These rare reports have
focused mainly on demyelinating polyradiculoneuropa-
thies and/or myelopathies secondary to intrathecal meth-
otrexate in children with acute lymphoblastic leukemia
(ALL) [1]. A case report is presented of sensory motor
axonal polyradiculoneuropathy with ascending paralysis
and cranial nerve involvement in an adult patient with
acute myelogenous leukemia (AML) following both
intrathecal methotrexate and intravenous Cytosine arabi-
noside (ARA-C).
Case history
The patient was a 53 year old Hispanic woman who orig-
inally presented at the end May in 2007 with complaints
of shoulder tightness and weakness in the neck and shoul-
ders for approximately 3 weeks duration along with short-
ness of breath. She presented to a local community
hospital where examination revealed an ill-appearing pale
woman with tachypnia. Subsequent investigations
showed thrombocytopenia with prominent leukocytosis
and numerous blasts on peripheral smear plus dissemi-
nated intravascular coagulation with subsequent diagno-
sis of acute myelogenous leukemia (please see Figure 1).
She underwent one session of leukophoresis and was
started on chemotherapy with Idarubicin (for the first 3
days) and ARA-C (for the first 7 days) along with allopu-
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rinol as tumor lysis prophylaxis and prophylactic intrath-
ecal methotrexate. Shortly after her initial presentation
and chemotherapy she suffered a left frontal lobe
ischemic stroke with right hemiparesis and aphasia. After
she responded to the leukophoresis and chemotherapy
and made some neurologic improvement with physical
therapy, she was transferred to the transitional care unit
where she made dramatic improvements in her speech
and balance and was able to walk up and down the hall-
way.
Approximately one month after her initial presentation
she began losing strength in her right leg. This was fol-
lowed by increased weakness in her right arm. A repeat
MRI of the brain showed no evidence of a new stroke.
Over the next three days she then went on to develop
weakness in all four extremities plus dysphasia and respi-
ratory difficulties, so that by the first weekend in July she
was essentially quadriplegic. Magnetic resonance imaging
studies of her cervical and lumbar spines showed no find-
ings that could explain all of her symptoms. She then pro-
gressed to respiratory failure requiring intubation.
Neurologic evaluation revealed diffuse severe weakness of
all extremities (1/4) with hypoactive reflexes (0/4). Extra
ocular muscles were intact without dysconjugate gaze,
and the pupils were briskly reactive and symmetric.
A lumbar puncture did not reveal any increased protein
(33 mg/dL with normal range 20–40 mg/dL) or abnormal
cells (red blood cells were 41 with normal < 5/cmm and
white blood cells 3 with normal 0–5/cmm), however
there were oligoclonal bands (36 with normal < 4) and an
elevated myelin basic protein (4.3 with normal range
0.07–4.10 ng/mL). Cerebrospinal fluid cytology was neg-
ative for any malignant cells. An electromyogram and
nerve conduction study showed absent sensory nerve
action potentials and absent compound motor action
potentials with diffuse denervation in all four extremities.
The presumptive diagnosis was Guillain-Barré syndrome
(GBS), and intravenous immunoglobulin (IVIG) was con-
sidered but felt to be contraindicated secondary to her
newly diagnosed AML and stroke. She was therefore given
4 sessions of plasmapharesis which was held on the fifth
session because of blood pressure fluctuations.
Over the next ten days or so she did not improve neuro-
logically, and in fact went on to develop right ptosis with
a dysreactive pupil and outward eye deviation thought to
be a third cranial nerve (CN 3) palsy, and a few days later
bilateral facial weakness. A repeat lumbar puncture (about
2 weeks after the last one) again did not reveal any
increased protein (27 mg/dL with normal range 20–40
mg/dL) or abnormal white blood cells (white blood cells
were 0/cmm and red blood cells were 1/cmm) and the cer-
ebrospinal fluid cytology was negative for any malignant
cells.
A sensory-motor neuropathy panel, myasthenia gravis
panel, and a Lambert-Eaton myasthenic panel both were
negative for any abnormal antibodies (Quest Diagnos-
tics).
A combined muscle and nerve biopsy was performed. The
sural nerve showed peripheral neuropathy with promi-
nent evidence of axonal degeneration with digestion
chambers and secondary dropout of myelinated fibers
which was moderately severe (please see Figure 2). There
was no evidence of vasculitis nor of endoneurial inflam-
mation. There was no evidence of amyloid deposition nor
of hypertrophic neuropathy. The muscle biopsy (right
thigh) showed diffuse Type II fiber atrophy and focal
myofiber degeneration (please see Figure 3).
The patient remained on a ventilator and essentially quad-
riplegic with a CN 3 palsy and bilateral facial weakness.
Approximately four weeks later she expired from pneu-
monia and secondary sepsis.
Discussion
The incidence of acute inflammatory demyelinating
polyradiculoneuropathy (AIDP) ranges from 0.6 to 2.4
cases per 100,000 population per year [2]. Cranial nerve
involvement ranges from 45–75% in different series.
Facial paresis, usually bilateral, is found in at least one
half of patients. Involvement of extraocular muscles and
Bone marrow core biopsy demonstrating markedly increased  cellularity with sheets of leukemic blasts morphologically  consistent with myelomonocytic leukemic blasts Figure 1
Bone marrow core biopsy demonstrating markedly 
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lower cranial nerves is seen less often. The proportion of
patients developing respiratory failure and requiring
assisted ventilation seems to increase with age and ranges
from 12% in epidemiological series to 30% in hospital-
based series [3].
Although the most common neurotoxic effects of intrave-
nous ARA-C involve the central nervous system, the asso-
ciation of ARA-C and polyneuropathy has also been
reported with both intravenous [4,5] and intrathecal
administration [6]. It can occur after a wide range of doses
[7] but is more commonly associated with high doses [8].
Predominantly sensory peripheral neuropathy is seen
with low dose ARA-C, whereas sensorimotor neuropathy
occurs after high-dose therapy. Symptoms can start from
hours to 2–3 weeks after initiation of therapy [6,9-11] and
can take several forms. A pure sensory or sensorimotor
neuropathy is most common. With higher doses it can
also produce both myelopathy and a rapidly progressive
ascending motor neuropathy which is typically monopha-
sic causing severe motor weakness, even quadriparesis
requiring ventilatory support. [6]. Indeed, high-dose ARA-
C has been reported to cause peripheral neuropathies
resembling both Guillain-Barré syndrome (as in our
patient), brachial plexopathies, and lateral rectus palsies
[9-11]. The overall incidence of demyelinating polyneu-
ropathy has been reported to be 1% [6]. The mechanism
of the neuropathic effect is unknown. ARA-C incorporates
into DNA and inhibits DNA polymerase and, thus, blocks
DNA synthesis. In the rapidly progressive form associated
with high-dose therapy, autopsy has showed demyelina-
tion with intact axons, raising the possibility of a direct
neurotoxic effect on Schwann cells. Electrophysiologic
studies demonstrate features consistent with both axonal
and demyelinating neuropathy [12,13]. This is consistent
with nerve biopsy results, which have shown axonal swell-
ing and segmental demyelination [8]. Openshaw reported
demyelination identified in luxol-fast blue sections of
peripheral nerve with Bielschowsky-stained sections
showing intact peripheral nerve axons on autopsy studies
[6].
Although central nervous system involvement is the most
common neurotoxicity associated with intrathecal meth-
otrexate therapy [9,14,15], transverse myelopathies [16]
and motor paraplegias have also been reported (mostly in
the pediatric literature) [1,17]. Anderson and colleagues
reported on a three-year old girl with ALL who in remis-
sion developed lower extremity paraparesis and areflexia
15 days after receiving intrathecal methotrexate, cytarab-
ine, and hydrocortisone. Spinal fluid, imaging, and elec-
trodiagnostic testing was consistent with a
polyradiculoneuritis and it was postulated that these find-
ings could represent selective ventral nerve root vulnera-
bility to intrathecal chemotherapy [18]. Rolf and
colleagues reported on two pediatric patients with acute
lymphoblastic leukemia who developed ascending
motoric paraplegia (AMP) following intrathecal chemo-
therapy. Both patients suffered from progressive weakness
of their lower extremities, and it was felt that there was
convincing evidence that AMP is caused by spinal cord
toxicity of intrathecally applied toxic agents such as
cytarabin and/or methotrexate leading to spinal demyeli-
Sural nerve (Epon) section demonstrating evidence of axonal  degeneration with digestion chambers and secondary drop- out of myelinated fibers Figure 2
Sural nerve (Epon) section demonstrating evidence 
of axonal degeneration with digestion chambers and 
secondary dropout of myelinated fibers.
Muscle biopsy (ATPase stain) of the right thigh showing dif- fuse Type II fiber atrophy and focal myofiber degeneration Figure 3
Muscle biopsy (ATPase stain) of the right thigh show-
ing diffuse Type II fiber atrophy and focal myofiber 
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nation as demonstrated by elevated myelin basic protein
in cerebrospinal fluid [1].
Werner [17] reported the following: Transient or perma-
nent paraplegia after the use of intrathecal (IT) methotrex-
ate (MTX) or cytosine arabinoside (ARA-C) for treatment
or prophylaxis of patients with meningeal leukemia is an
unusual complication, with an incidence of less than 3%
among such patients. Only 15 cases involving IT MTX
have been documented and even fewer with IT ARA-C.
Three patients were studied who developed permanent or
ascending myelopathy from treatment of their leukemia
or rhabdomyosarcoma with IT chemotherapy. The
patients' ages ranged from 7 to 62 years. Two of the three
patients had electromyographic examinations. These
revealed a primary motor neuron degeneration or a polyr-
adiculopathy, superimposed on a mild axonal peripheral
neuropathy associated with vincristine therapy. This is
consistent with other electromyographic studies. Two of
the patients showed an elevation of the cerebral spinal
fluid (CSF) protein before development of paraplegia;
one also showed a rise in myelin basic protein associated
with his myelopathy. Neuropathologic findings suggest
demyelination as the primary process leading to myelop-
athy. Increasing evidence has shown that total CSF pro-
tein, or more specifically, the myelin basic protein, may be
elevated before development of paraplegia. Routine serial
testing of the CSF for total protein was suggested as a
screening test during therapy.
It should also be mentioned that GBS can be associated
with leukemia alone. Vembu and colleagues [19] reported
a case of severe GBS in a 32-year old female patient diag-
nosed with acute lymphoblastic leukemia who was on
chemotherapy. The clinical features, nerve conduction
and the cerebrospinal fluid studies were consistent with
acute GBS and it was felt that the fulminate neuropathy
was most likely due to the association between GBS and
leukemia rather than chemotherapeutic neurotoxicity as
the patient responded to IVIG.
The patient presented developed a third cranial nerve
palsy which then progressed to a bilateral facial nerve
palsy. At first it was felt that this may be a vasculitis with
multifocal involvement. However, given the setting of her
motor quadriplegia, respiratory failure along with the vas-
culitis-negative sural nerve biopsy results it was most
likely a manifestation of AIDP or a GBS-like syndrome.
Facial paresis, usually bilateral, is found in at least one
half of patients [2] and other cranial nerve involvement
has also been reported. Given the time course it was felt
that the combination of the intravenous ARA-C with the
intrathecal methotrexate caused her ascending sensory
motor polyradiculoneuropathy with motor quadriplegia,
perhaps by selective ventral nerve root vulnerability to
intrathecal chemotherapy as has been suggested by Ander-
son and colleagues [18]. There was no evidence of mye-
lopathy via MR imaging and the electrodiagnostic studies
were consistent with diffuse acute axonal loss. The nega-
tive cytology results in the CSF with multiple lumbar
punctures makes diffuse neoplastic meningitis less likely.
Nerve biopsy confirmed predominately axonal loss
changes with a secondary drop out of myelinated fibers,
and muscle biopsy revealed angulated small fibers con-
sistent with neurogenic atrophy. Unfortunately she did
not respond to plasma exchange. It is puzzling why there
was never any elevation of the spinal fluid total protein
even with two samples taken two weeks apart. There was
however on both spinal fluid samples elevated OCB's and
MBP as has been previously reported [1,17,20]. Lastly, a
direct effect from the AML was felt to be unlikely because
the biopsy didn't reveal any leukemic cell infiltration or
perilymphocytic infiltrates.
Conclusion
Although there have been occasional pediatric case
reports, this is an interesting case of ascending sensory
motor polyradiculoneuropathy with cranial nerve
involvement in an adult patient with AML following intra-
venous ARA-C and intrathecal methotrexate. The polyra-
diculoneuropathy appears to have been secondary to
predominant axonal loss rather than demyelination as
reported in most other studies.
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